NASDAQ:FOLD - Amicus Therapeutics Stock Price, Price Target & More

$14.64 -0.13 (-0.88 %)

(As of 04/19/2018 04:00 PM ET)

Previous Close$14.64

Today's Range$14.38 - $15.06

52-Week Range$6.41 - $17.40

Volume2.34 million shs

Average Volume3.08 million shs

Market Capitalization$2.77 billion

P/E Ratio-5.01

Dividend YieldN/A

Beta1.46

About Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:FOLD

CUSIP03152W10

Webwww.amicusrx.com

Phone609-662-2000

Debt

Debt-to-Equity Ratio0.47%

Current Ratio5.60%

Quick Ratio5.53%

Price-To-Earnings

Trailing P/E Ratio-5.01

Forward P/E Ratio-10.76

P/E GrowthN/A

Sales & Book Value

Annual Sales$36.93 million

Price / Sales74.52

Cash FlowN/A

Price / CashN/A

Book Value$2.12 per share

Price / Book6.91

Profitability

EPS (Most Recent Fiscal Year)($2.92)

Net Income$-284,000,000.00

Net Margins-769.03%

Return on Equity-71.06%

Return on Assets-29.39%

Miscellaneous

Employees325

Outstanding Shares187,970,000

How to Become a New Pot Stock Millionaire

Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics (NASDAQ:FOLD) posted its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.11. The biopharmaceutical company earned $14.73 million during the quarter, compared to the consensus estimate of $14.50 million. Amicus Therapeutics had a negative return on equity of 71.06% and a negative net margin of 769.03%. View Amicus Therapeutics' Earnings History.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Amicus Therapeutics.

What price target have analysts set for FOLD?

7 brokerages have issued 1-year target prices for Amicus Therapeutics' shares. Their forecasts range from $15.00 to $24.00. On average, they expect Amicus Therapeutics' share price to reach $19.50 in the next year. View Analyst Ratings for Amicus Therapeutics.

Are investors shorting Amicus Therapeutics?

Amicus Therapeutics saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 27,987,959 shares, an increase of 3.8% from the March 15th total of 29,104,959 shares. Based on an average daily trading volume, of 2,143,412 shares, the days-to-cover ratio is currently 13.1 days. Approximately 15.4% of the shares of the stock are sold short.

Who are some of Amicus Therapeutics' key competitors?

Some companies that are related to Amicus Therapeutics include Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Gal�pagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), Blueprint Medicines (BPMC), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND), Advanced Accelerator Application (AAAP), Array Biopharma (ARRY), Tesaro (TSRO), Clovis Oncology (CLVS), Ascendis Pharma (ASND) and Emergent BioSolutions (EBS).

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the folowing people:

Mr. John F. Crowley, Chairman and Chief Exec. Officer (Age 51)
Mr. Bradley L. Campbell, Pres and Chief Operating Officer (Age 42)
Mr. William D. Baird III, Chief Financial Officer (Age 46)
Dr. Hung Do Ph.D., Chief Science Officer (Age 50)
Dr. Jay A. Barth M.D., Chief Medical Officer (Age 54)

Has Amicus Therapeutics been receiving favorable news coverage?

Media headlines about FOLD stock have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amicus Therapeutics earned a coverage optimism score of 0.03 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.42 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include PRUDENTIAL FINANCIAL INC (6.20%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $14.64.

How big of a company is Amicus Therapeutics?

Amicus Therapeutics has a market capitalization of $2.77 billion and generates $36.93 million in revenue each year. The biopharmaceutical company earns $-284,000,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Amicus Therapeutics employs 325 workers across the globe.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]

MarketBeat Community Rating for Amicus Therapeutics (FOLD)

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		310 (Vote Outperform)
Underperform Votes:		179 (Vote Underperform)
Total Votes:		489

MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe FOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Amicus Therapeutics (NASDAQ:FOLD) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

7 Wall Street analysts have issued ratings and price targets for Amicus Therapeutics in the last 12 months. Their average twelve-month price target is $19.50, suggesting that the stock has a possible upside of 33.20%. The high price target for FOLD is $24.00 and the low price target for FOLD is $15.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.86	2.86	2.86	2.86
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$19.50	$19.50	$18.6429	$18.0714
Price Target Upside:	33.20% upside	17.75% upside	20.20% upside	13.09% upside

Amicus Therapeutics (NASDAQ:FOLD) Consensus Price Target History

Price Target History for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/8/2018	Leerink Swann	Boost Price Target	Outperform -> Outperform	$20.00 -> $24.00	High
2/7/2018	Robert W. Baird	Set Price Target	Buy	$20.00	High
1/10/2018	Cowen	Reiterated Rating	Buy	$22.00	Medium
10/6/2017	Goldman Sachs	Reiterated Rating	Neutral -> Neutral	$17.00	N/A
10/5/2017	Chardan Capital	Reiterated Rating	Buy	$16.50 -> $18.50	N/A
10/4/2017	JPMorgan Chase	Reiterated Rating	Overweight		N/A
10/4/2017	Bank of America	Boost Price Target	Buy	$15.00 -> $20.00	High

(Data available from 4/19/2016 forward)

Amicus Therapeutics (NASDAQ:FOLD) Earnings History and Estimates Chart

Earnings by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD) Earnings Estimates

2018 EPS Consensus Estimate: ($1.47)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.37)	($0.37)	($0.37)
Q2 2018	1	($0.37)	($0.37)	($0.37)
Q3 2018	1	($0.37)	($0.37)	($0.37)
Q4 2018	1	($0.36)	($0.36)	($0.36)

Amicus Therapeutics (NASDAQ FOLD) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018		($0.33)					N/A
2/28/2018	Q4 2017	($0.30)	($0.41)	$14.50 million	$14.73 million	View	Listen
11/8/2017	Q3 2017	($0.31)	($0.41)	$9.02 million	$10.90 million	View	N/A
8/7/2017	Q2 2017	($0.37)	($0.34)	$6.96 million	$7.16 million	View	Listen
5/9/2017	Q1 2017	($0.37)	($0.39)	$4.16 million	$4.20 million	View	Listen
3/1/2017	Q4 2016	($0.33)	($0.32)	$3.16 million	$2.83 million	View	Listen
11/7/2016	Q3	($0.31)	($0.33)	$1.71 million	$2.10 million	View	Listen
8/9/2016	Q2	($0.33)	($0.40)	$0.17 million		View	N/A
5/3/2016	Q1	($0.34)	($0.35)			View	Listen
2/26/2016	Q4 2015	($0.31)	($0.35)			View	N/A
11/3/2015	Q3	($0.25)	($0.32)			View	N/A
8/5/2015	Q215	($0.24)	($0.26)			View	N/A
5/5/2015	Q115	($0.14)	($0.25)	$0.50 million		View	N/A
3/3/2015	Q414	($0.18)	($0.24)	$0.48 million		View	N/A
11/6/2014	Q3 2014	($0.21)	($0.22)	$1.00 million	$0.29 million	View	N/A
8/7/2014	Q2 2014	($0.24)	($0.23)		$0.48 million	View	N/A
5/5/2014	Q1 2014	($0.23)	($0.25)	$0.20 million	$0.46 million	View	N/A
3/3/2014	Q4 13	($0.32)	($0.22)		$0.32 million	View	N/A
11/11/2013	Q3	($0.3220)	($0.29)		$0.04 million	View	N/A
8/7/2013	Q2 2013	($0.35)	($0.31)			View	N/A
5/9/2013	Q1 2013	($0.30)	($0.34)			View	N/A
3/12/2013	Q4 2012	($0.36)	($0.23)			View	N/A
11/5/2012	Q312	($0.24)	($0.31)	$8.82 million	$5.80 million	View	N/A
8/7/2012	Q2 2012	($0.23)	($0.20)			View	N/A
5/10/2012	Q1 2012	($0.34)	($0.28)			View	N/A
2/13/2012	Q4 2011	($0.37)	$0.23			View	N/A
11/1/2011	Q3 2011	($0.33)	($0.38)			View	N/A
8/8/2011	Q2 2011	($0.32)	($0.31)			View	N/A
5/4/2011	Q1 2011	($0.35)	($0.29)			View	N/A
2/14/2011	Q4 2010	($0.15)	($0.45)			View	N/A
11/8/2010	Q3 2010	($0.49)	($0.48)			View	N/A
8/5/2010	Q2 2010	($0.53)	($0.41)			View	N/A
5/6/2010	Q1 2010	($0.57)	($0.54)			View	N/A
2/16/2010	Q4 2009	($0.59)	$1.45			View	N/A
10/29/2009	Q3 2009	($0.71)	($0.59)			View	N/A
8/5/2009	Q2 2009	($0.63)	($0.60)			View	N/A
5/7/2009	Q1 2009	($0.60)	($0.55)			View	N/A
2/5/2009	Q4 2008	($0.54)	($0.63)			View	N/A
11/3/2008	Q3 2008	($0.44)	($0.36)			View	N/A
8/7/2008	Q2 2008	($0.45)	($0.41)			View	N/A
5/13/2008	Q1 2008	($0.39)	($0.35)			View	N/A
1/29/2008	Q4 2007	($0.35)	($0.53)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Amicus Therapeutics (NASDAQ:FOLD) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Amicus Therapeutics (NASDAQ FOLD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.40%

Insider Trading History for Amicus Therapeutics (NASDAQ:FOLD)

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ FOLD) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/17/2018	Hung Do	Insider	Sell	50,000	$15.00	$750,000.00	446,771
4/16/2018	Michael Raab	Director	Sell	5,000	$14.41	$72,050.00	10,814
4/12/2018	Jay Barth	Insider	Sell	5,000	$14.72	$73,600.00	90,409
4/2/2018	Kurt J Andrews	SVP	Sell	5,000	$14.27	$71,350.00	45,469
4/2/2018	William D Baird III	CFO	Sell	10,000	$14.26	$142,600.00	127,662
3/12/2018	Jay Barth	Insider	Sell	5,000	$15.05	$75,250.00	90,409
3/9/2018	Daphne Quimi	SVP	Sell	8,750	$15.00	$131,250.00	73,082
3/5/2018	Perceptive Advisors Llc	Major Shareholder	Buy	335,827	$13.56	$4,553,814.12
3/1/2018	Daphne Quimi	SVP	Sell	8,149	$14.06	$114,574.94	72,481
3/1/2018	Life Sciences Maste Perceptive	Major Shareholder	Buy	100,000	$13.69	$1,369,000.00
1/23/2018	Jay Barth	Insider	Sell	20,000	$16.80	$336,000.00	105,409
1/22/2018	Bradley L Campbell	COO	Sell	32,500	$15.92	$517,400.00	186,600
1/2/2018	Daphne Quimi	SVP	Sell	8,000	$14.72	$117,760.00	62,676
1/2/2018	Donald J Hayden Jr	Director	Sell	20,000	$15.00	$300,000.00	25,814
1/2/2018	Jay Barth	Insider	Sell	5,000	$14.71	$73,550.00	69,184
1/2/2018	William D Baird III	CFO	Sell	10,000	$14.72	$147,200.00	105,121
12/29/2017	John F Crowley	CEO	Sell	18,970	$14.75	$279,807.50
12/29/2017	John F Crowley	CEO	Sell	5,920	$14.75	$87,320.00	341,051
12/21/2017	John F Crowley	CEO	Sell	65,581	$13.51	$885,999.31	393,076
12/11/2017	John F Crowley	CEO	Sell	12,206	$13.52	$165,025.12	340,207
12/4/2017	John F Crowley	CEO	Sell	47,213	$13.61	$642,568.93	375,214
12/1/2017	Jay Barth	Insider	Sell	5,000	$13.59	$67,950.00	69,184
10/18/2017	John F Crowley	CEO	Sell	71,735	$14.75	$1,058,091.25	380,723
10/16/2017	John F Crowley	CEO	Sell	449,295	$14.33	$6,438,397.35	380,723
10/12/2017	Daphne Quimi	SVP	Sell	7,000	$14.25	$99,750.00
10/12/2017	Hung Do	Insider	Sell	50,194	$14.25	$715,264.50
10/12/2017	Michael Raab	Director	Sell	10,000	$14.25	$142,500.00
10/12/2017	William D Baird III	CFO	Sell	40,000	$14.25	$570,000.00
9/26/2017	John F Crowley	CEO	Buy	1,395	$14.36	$20,032.20	328,001
7/13/2017	Life Sciences Maste Perceptive	Major Shareholder	Buy	1,500,000	$12.25	$18,375,000.00
6/19/2017	Jay Barth	Insider	Sell	30,000	$10.00	$300,000.00	64,184
5/19/2017	Hung Do	Insider	Sell	29,914	$8.00	$239,312.00	474,438
3/2/2017	Bradley L Campbell	COO	Sell	49,050	$8.00	$392,400.00	127,475
1/13/2017	Hung Do	Insider	Sell	25,000	$6.00	$150,000.00	559,266
12/30/2016	Perceptive Advisors Llc	Major Shareholder	Buy	94,750	$4.96	$469,960.00
12/29/2016	Perceptive Advisors Llc	Major Shareholder	Buy	142,125	$4.87	$692,148.75
12/23/2016	Perceptive Advisors Llc	Major Shareholder	Buy	85,275	$4.81	$410,172.75
12/22/2016	Perceptive Advisors Llc	Major Shareholder	Buy	189,500	$4.51	$854,645.00
11/9/2016	Daphne Quimi	SVP	Sell	8,546	$8.00	$68,368.00	24,189
11/1/2016	Hung Do	Insider	Sell	25,000	$7.00	$175,000.00	533,453
10/3/2016	Hung Do	Insider	Sell	25,000	$7.25	$181,250.00	558,453
9/20/2016	William D Baird III	CFO	Sell	20,500	$8.00	$164,000.00	56,450
9/6/2016	Hung Do	Insider	Sell	25,000	$7.00	$175,000.00	583,453
8/25/2016	Perceptive Advisors Llc	Insider	Sell	1,100,000	$6.81	$7,491,000.00
8/4/2016	Jay Barth	Insider	Sell	10,458	$7.00	$73,206.00	15,000
7/27/2016	Jay Barth	Insider	Sell	20,916	$7.00	$146,412.00	25,458
6/2/2016	Ellen Rosenberg	General Counsel	Buy	15,000	$7.67	$115,050.00
11/10/2015	Margaret G Mcglynn	Director	Buy	10,000	$10.27	$102,700.00	10,000
10/7/2015	Perceptive Advisors Llc	Major Shareholder	Buy	50,000	$6.27	$313,500.00
10/6/2015	Perceptive Advisors Llc	Major Shareholder	Buy	750,000	$6.71	$5,032,500.00
10/1/2015	Kenneth Peist	VP	Sell	10,000	$13.14	$131,400.00	3,187
9/21/2015	Bradley L. Campbell	COO	Sell	13,001	$16.78	$218,156.78	156,575
9/21/2015	William D. Baird III	CFO	Sell	15,236	$16.78	$255,660.08	56,575
9/15/2015	Hung Do	Insider	Sell	25,000	$17.75	$443,750.00	720,953
9/14/2015	Daphne Quimi	VP	Sell	2,500	$18.08	$45,200.00	5,688
7/16/2015	John F Crowley	CEO	Sell	16,025	$16.00	$256,400.00
7/14/2015	John F Crowley	CEO	Sell	142,250	$15.03	$2,138,017.50
7/13/2015	Glenn Sblendorio	Director	Sell	10,000	$15.00	$150,000.00
7/13/2015	John F Crowley	CEO	Sell	7,750	$15.01	$116,327.50
7/13/2015	Ken Valenzano	SVP	Sell	15,000	$15.00	$225,000.00
7/8/2015	Dipal Doshi	SVP	Sell	6,250	$13.87	$86,687.50
7/1/2015	Jayne Gershkowitz	SVP	Sell	10,649	$13.97	$148,766.53
7/1/2015	Kenneth Peist	VP	Sell	10,000	$13.98	$139,800.00
6/23/2015	Donald J Hayden Jr	Director	Sell	55,000	$14.01	$770,550.00
6/22/2015	Jeff Castelli	SVP	Sell	18,981	$13.94	$264,595.14
6/19/2015	Bradley L Campbell	COO	Sell	13,000	$13.26	$172,380.00
6/19/2015	Enrique Dilone	SVP	Sell	14,045	$13.26	$186,236.70
6/19/2015	William D Baird III	CFO	Sell	15,235	$13.26	$202,016.10
6/15/2015	Jeff Castelli	SVP	Sell	7,377	$14.17	$104,532.09
6/15/2015	Julie Yu	VP	Sell	8,195	$14.17	$116,123.15
6/8/2015	Jeff Castelli	SVP	Sell	17,312	$12.87	$222,805.44
6/8/2015	John F Crowley	CEO	Sell	55,000	$13.01	$715,550.00
5/11/2015	Jeff Castelli	SVP	Sell	10,000	$10.84	$108,400.00
5/11/2015	Kenneth Peist	VP	Sell	12,500	$10.84	$135,500.00
5/11/2015	William D Baird III	CFO	Sell	24,800	$10.84	$268,832.00
4/15/2015	Glenn Sblendorio	Director	Sell	20,000	$12.50	$250,000.00
4/15/2015	Ken Valenzano	VP	Sell	5,000	$12.50	$62,500.00
4/10/2015	John F Crowley	CEO	Sell	11,678	$12.00	$140,136.00
4/1/2015	Jeff Castelli	VP	Sell	9,489	$10.69	$101,437.41
1/5/2015	Jeff Castelli	VP	Sell	4,667	$9.00	$42,003.00
12/4/2014	John F Crowley	CEO	Sell	89,000	$8.36	$744,040.00
11/25/2014	Bradley L Campbell	COO	Sell	7,250	$8.00	$58,000.00
11/25/2014	Jeff Castelli	VP	Sell	8,103	$8.00	$64,824.00
11/25/2014	William D Baird III	CFO	Sell	10,000	$8.00	$80,000.00
11/19/2014	Perceptive Advisors Llc	Major Shareholder	Buy	2,100,000	$6.50	$13,650,000.00
10/27/2014	Plc Glaxosmithkline	Major Shareholder	Sell	11,315,825	$5.29	$59,860,714.25
10/3/2014	Jeff Castelli	VP	Sell	8,552	$7.00	$59,864.00
10/3/2014	William D Baird III	CFO	Sell	10,000	$7.00	$70,000.00
10/2/2014	Julie Yu	VP	Sell	4,759	$5.99	$28,506.41
9/29/2014	Daphne Quimi	VP	Sell	10,738	$6.10	$65,501.80
9/29/2014	William D Baird III	CFO	Sell	25,311	$6.09	$154,143.99
8/27/2014	Glenn Sblendorio	Director	Sell	10,000	$6.50	$65,000.00
8/27/2014	Jayne Gershkowitz	VP	Sell	5,000	$7.00	$35,000.00
8/25/2014	Bradley L Campbell	COO	Sell	7,000	$6.00	$42,000.00
8/25/2014	Jayne Gershkowitz	VP	Sell	5,000	$6.00	$30,000.00
8/20/2014	Bradley L Campbell	COO	Sell	18,750	$5.40	$101,250.00
8/20/2014	Enrique Dilone	VP	Sell	12,810	$5.40	$69,174.00
6/30/2014	Perceptive Advisors Llc	Major Shareholder	Buy	4,000,000	$3.50	$14,000,000.00
11/20/2013	Plc Glaxosmithkline	major shareholder	Buy	1,500,000	$2.00	$3,000,000.00
3/15/2013	Sol J Barer	Director	Buy	25,000	$3.40	$85,000.00
11/13/2012	Joan Winterbottom	SVP	Buy	1,665	$4.54	$7,559.10

(Data available from 1/1/2013 forward)

Amicus Therapeutics (NASDAQ FOLD) News Headlines

Source:

Date	Headline
	Amicus Therapeutics (FOLD) Insider Hung Do Sells 50,000 Shares www.americanbankingnews.com - April 19 at 7:34 PM
	Zacks Investment Research Downgrades Amicus Therapeutics (FOLD) to Sell www.americanbankingnews.com - April 19 at 12:28 AM
	Amicus Therapeutics (FOLD) Director Sells $72,050.00 in Stock www.americanbankingnews.com - April 18 at 7:49 PM
	Jay Barth Sells 5,000 Shares of Amicus Therapeutics (FOLD) Stock www.americanbankingnews.com - April 16 at 7:14 PM
	Portfolio Review: Continued Market Outperformance In Q1 2018 seekingalpha.com - April 15 at 8:43 AM
	Amicus Therapeutics (FOLD) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - April 15 at 3:25 AM
	$16.78 Million in Sales Expected for Amicus Therapeutics (FOLD) This Quarter www.americanbankingnews.com - April 14 at 4:39 AM
	Amicus Therapeutics (FOLD) Rating Lowered to Buy at BidaskClub www.americanbankingnews.com - April 14 at 12:49 AM
	Amicus Therapeutics (FOLD) Lifted to "Buy" at BidaskClub www.americanbankingnews.com - April 13 at 11:05 AM
	Zacks: Analysts Expect Amicus Therapeutics (FOLD) Will Post Earnings of -$0.36 Per Share www.americanbankingnews.com - April 12 at 5:23 AM
	Amicus Therapeutics Sees Unusually High Options Volume (FOLD) www.americanbankingnews.com - April 11 at 7:06 AM
	Amicus Therapeutics (FOLD) PT Raised to $17.50 www.americanbankingnews.com - April 10 at 11:38 PM
	Amicus Therapeutics (FOLD) Upgraded at Zacks Investment Research www.americanbankingnews.com - April 7 at 3:52 PM
	Amicus Therapeutics (FOLD) SVP Sells $71,350.00 in Stock www.americanbankingnews.com - April 4 at 11:18 PM
	William D. Baird III Sells 10,000 Shares of Amicus Therapeutics (FOLD) Stock www.americanbankingnews.com - April 4 at 11:17 PM
	Amicus Therapeutics (FOLD) Upgraded to "Buy" at ValuEngine www.americanbankingnews.com - April 3 at 3:35 PM
	Amicus Therapeutics (FOLD) Rating Lowered to Hold at BidaskClub www.americanbankingnews.com - March 30 at 2:19 PM
	3 Biotech Stocks a Pro Is Buying Now www.barrons.com - March 30 at 8:16 AM
	[$$] 3 Biotech Stocks a Pro Is Buying Now finance.yahoo.com - March 30 at 8:16 AM
	Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan finance.yahoo.com - March 30 at 8:16 AM
	Amicus Therapeutics, Inc. (FOLD) Short Interest Update www.americanbankingnews.com - March 29 at 3:10 AM
	Amicus Therapeutics (FOLD) Raised to "Hold" at Zacks Investment Research www.americanbankingnews.com - March 27 at 11:28 PM
	Amicus Therapeutics (FOLD) Upgraded to "Hold" at ValuEngine www.americanbankingnews.com - March 25 at 5:54 PM
	Zacks Investment Research Upgrades Amicus Therapeutics (FOLD) to "Hold" www.americanbankingnews.com - March 24 at 12:28 AM
	Amicus Therapeutics Announces Approval of Galafold® (Migalastat ... - GlobeNewswire (press release) globenewswire.com - March 23 at 8:00 AM
	Amicus Therapeutics' Galafold OK'd in Japan for Fabry disease seekingalpha.com - March 23 at 7:13 AM
	Amicus Therapeutics, Inc. (FOLD) Receives Consensus Rating of "Buy" from Analysts www.americanbankingnews.com - March 21 at 3:28 AM
	Amicus Therapeutics (FOLD) Presents At Barclays Global Healthcare Conference 2018 - Slideshow seekingalpha.com - March 16 at 6:47 PM
	After Hours Most Active for Mar 14, 2018 : QQQ, FOLD, F, MSFT, QEP, GM, USMC, BEN, CMCSA, BSX, CNP, EXEL - Nasdaq www.nasdaq.com - March 14 at 5:42 PM
	Jay Barth Sells 5,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock www.americanbankingnews.com - March 13 at 8:32 PM
	Amicus Therapeutics, Inc. (FOLD) SVP Sells $131,250.00 in Stock www.americanbankingnews.com - March 12 at 7:57 PM
	$16.78 Million in Sales Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter www.americanbankingnews.com - March 11 at 9:35 AM
	Brokerages Anticipate Amicus Therapeutics, Inc. (FOLD) Will Post Earnings of -$0.36 Per Share www.americanbankingnews.com - March 9 at 1:10 AM
	Amicus Therapeutics, Inc. (FOLD) Major Shareholder Perceptive Advisors Llc Buys 335,827 Shares www.americanbankingnews.com - March 7 at 6:16 PM
	Amicus Therapeutics (FOLD) Lifted to Hold at Zacks Investment Research www.americanbankingnews.com - March 6 at 10:52 PM
	Amicus Therapeutics, Inc. (FOLD) SVP Daphne Quimi Sells 8,149 Shares www.americanbankingnews.com - March 5 at 7:18 PM
	Life Sciences Maste Perceptive Acquires 100,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock www.americanbankingnews.com - March 5 at 6:22 PM
	Amicus Therapeutics, Inc. (FOLD) Stake Boosted by Swiss National Bank www.americanbankingnews.com - March 5 at 4:04 PM
	Sectoral Asset Management Inc Acquires 437,899 Shares of Amicus Therapeutics, Inc. (FOLD) www.americanbankingnews.com - March 5 at 3:33 PM
	Leerink Swann Weighs in on Amicus Therapeutics, Inc.'s Q1 2018 Earnings (FOLD) www.americanbankingnews.com - March 5 at 2:22 AM
	State of Wisconsin Investment Board Raises Position in Amicus Therapeutics, Inc. (FOLD) www.americanbankingnews.com - March 4 at 9:32 AM
	Amicus Therapeutics, Inc. (FOLD) Shares Bought by Schwab Charles Investment Management Inc. www.americanbankingnews.com - March 3 at 5:56 AM
	Head-To-Head Survey: Amicus Therapeutics (FOLD) and Aquinox Pharmaceuticals (AQXP) www.americanbankingnews.com - March 3 at 1:12 AM
	Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates - GlobeNewswire (press release) globenewswire.com - March 2 at 8:24 AM
	Amicus Therapeutics (FOLD) Posts Earnings Results, Misses Estimates By $0.11 EPS www.americanbankingnews.com - March 1 at 11:18 AM
	270,900 Shares in Amicus Therapeutics, Inc. (FOLD) Purchased by Spark Investment Management LLC www.americanbankingnews.com - February 28 at 4:56 PM
	1,859,320 Shares in Amicus Therapeutics, Inc. (FOLD) Acquired by Carillon Tower Advisers Inc. www.americanbankingnews.com - February 28 at 5:32 AM
	Amicus Therapeutics, Inc. (FOLD) Shares Bought by American Century Companies Inc. www.americanbankingnews.com - February 28 at 4:18 AM
	Amicus Therapeutics Launches Healing Beyond Disease™ Initiatives to Change People’s Lives Living with Rare Diseases finance.yahoo.com - February 27 at 5:43 PM
	Amicus Therapeutics, Inc. (FOLD) Receives Consensus Rating of "Buy" from Brokerages www.americanbankingnews.com - February 24 at 3:40 AM

Amicus Therapeutics (NASDAQ:FOLD) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Amicus Therapeutics (NASDAQ:FOLD) Income Statement, Balance Sheet and Cash Flow Statement

Amicus Therapeutics (NASDAQ FOLD) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff